BUSINESSFORTUNE
AstraZeneca said to have explored Bristol Myers merger
AstraZeneca Plc explored an acquisition of Bristol Myers Squibb Co., which could create one of the world's largest drugmakers. Bristol Myers Squibb, with a $133 billion market capitalization, faces patent losses for key drugs like Eliquis and Opdivo, while AstraZeneca has a market value of about £196 billion. Bristol recently reported record quarterly sales of $13 billion driven by newer treatments.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca Said to Have Explored Bristol Myers Merger
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
- STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
- Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration